LLNL Scientists Use Engineered Bone Marrow for Cancer Research and Treatment
September 26, 2023
September 26, 2023
LIVERMORE, California, Sept. 26 (TNSres) -- The U.S. Department of Energy's Lawrence Livermore National Laboratory issued the following news release:
Osteosarcoma (OS) is the most common primary malignant bone cancer in children and adolescents. While many other cancers now have promising therapeutic advances, treatment options for OS have remained unchanged since the introduction of standard chemotherapeutics and offer less than a 25% five-year survival rate for those with met . . .
Osteosarcoma (OS) is the most common primary malignant bone cancer in children and adolescents. While many other cancers now have promising therapeutic advances, treatment options for OS have remained unchanged since the introduction of standard chemotherapeutics and offer less than a 25% five-year survival rate for those with met . . .